HC Wainwright Forecasts OTCMKTS:MDNAF FY2030 Earnings

Medicenna Therapeutics Corp. (OTCMKTS:MDNAF) – Equities researchers at HC Wainwright cut their FY2030 earnings estimates for Medicenna Therapeutics in a research note issued to investors on Thursday, July 2nd. HC Wainwright analyst S. Ramakanth now expects that the company will earn $0.22 per share for the year, down from their previous estimate of $0.23. The consensus estimate for Medicenna Therapeutics’ current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Medicenna Therapeutics’ FY2031 earnings at $0.33 EPS.

Medicenna Therapeutics Stock Down 8.6%

Shares of OTCMKTS:MDNAF opened at $0.28 on Friday. The business has a fifty day moving average of $0.35. The company has a market cap of $25.38 million, a price-to-earnings ratio of -1.72 and a beta of 1.75. Medicenna Therapeutics has a one year low of $0.25 and a one year high of $1.43.

Medicenna Therapeutics (OTCMKTS:MDNAF) last announced its earnings results on Thursday, June 25th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.05).

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp. is a clinical-stage biopharmaceutical company focused on developing next-generation cytokine-based immunotherapies for cancer and central nervous system disorders. The company applies protein-engineering approaches to create engineered cytokine therapeutics designed to enhance anti-tumor activity while reducing systemic toxicity, aiming to broaden the therapeutic window for immunomodulatory agents.

Medicenna’s pipeline includes proprietary candidates such as MDNA55, an engineered interleukin-4 (IL-4) receptor-targeted fusion protein developed for intratumoral treatment of recurrent glioblastoma and other brain tumors, and MDNA11, a long-acting engineered interleukin-2 (IL-2) “superkine” intended to stimulate anti-tumor immune responses in solid tumors with an improved safety profile.